Skip to main content

Ultresa FDA Approval History

FDA Approved: Yes (Discontinued) (First approved March 1, 2012)
Brand name: Ultresa
Generic name: pancrelipase
Dosage form: Delayed Release Capsules
Company: Allergan plc
Treatment for: Pancreatic Exocrine Dysfunction

Marketing Status: Discontinued

Ultresa (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.

Development timeline for Ultresa

Mar  1, 2012Approval Aptalis Pharma Announces FDA Approval of Ultresa (Pancrelipase) Delayed Release Capsules

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.